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Abstract Lower limb spasticity in post-stroke patients
can impair ambulation and reduces activities of daily living
(ADL) performance of patients. Botulinum toxin type A
(BoNTA) has been shown effective for upper limb spas-
ticity. This study assesses the treatment of lower limb
spasticity in a large placebo-controlled clinical trial. In this
multicenter, randomized, double-blind, parallel-group,
placebo-controlled study, we evaluate the efﬁcacy and
safety of one-time injections of botulinum toxin type A
(BoNTA) in Japanese patients with post-stroke lower limb
spasticity. One hundred twenty patients with lower limb
spasticity were randomized to a single treatment with
BoNTA 300 U or placebo. The tone of the ankle ﬂexor was
assessed at baseline and through 12 weeks using the
Modiﬁed Ashworth Scale (MAS). Gait pattern and speed of
gait were also assessed. The primary endpoint was area
under the curve (AUC) of the change from baseline in the
MAS ankle score. Signiﬁcant improvement in spasticity
with BoNTA 300 U was demonstrated by a mean differ-
ence in the AUC of the change from baseline in the MAS
ankle score between the BoNTA and placebo groups
(-3.428; 95% CIs, -5.841 to -1.016; p = 0.006; t test). A
signiﬁcantly greater decrease from baseline in the MAS
ankle score was noted at weeks 4, 6 and 8 in the BoNTA
group compared to the placebo group (p\0.001). Sig-
niﬁcant improvement in the Clinicians Global Impression
was noted by the investigator at weeks 4, 6 and 8
(p = 0.016–0.048, Wilcoxon test), but not by the patient or
physical/occupational therapist. Assessments of gait pat-
tern using the Physician’s Rating Scale and speed of gait
revealed no signiﬁcant treatment differences but showed a
tendency towards improvement with BoNTA. No marked
difference was noted in the frequency of treatment-related
adverse events between BoNTA and placebo groups. This
was the ﬁrst large-scale trial to indicate that BoNTA sig-
niﬁcantly reduced spasticity in lower limb muscles.
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Introduction
Spasticity is deﬁned by Lance as a motor disorder char-
acterized by a velocity-dependent increase in tonic stretch
reﬂexes (muscle tone) with exaggerated tendon jerks,
resulting from hyperexcitability of the stretch reﬂex, as one
of the components of upper motor neuron syndrome [1].
BoNTA (botulinum toxin type A, onabotulinumtoxinA
1)
is a speciﬁc formulation of a locally injected muscle
relaxant whose active ingredient is botulinum toxin type A
produced by Clostridium botulinum. Botulinum toxin type
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motor nerve terminal and is taken up by the nerve cells
where the light chain of toxin cleaves a synaptosome-
associated protein (SNAP-25) to inhibit acetylcholine
release from the nerve terminal. As its muscle relaxant
effect is exerted in the hypertonic muscle, BoNTA offers
an alternative treatment for spastic patients who have dif-
ﬁculty with oral muscle relaxants that can produce gen-
eralized weakness and drowsiness, cognitive impairment,
and/or a reduced level of arousal. Locally injected BoNTA
is expected to improve limb position and functional ability,
and reduce pain in patients with spasticity. Moreover,
BoNTA has no sedative action, unlike existing oral an-
tispastic treatments, and therefore can be used in patients
with cognitive impairment or a reduced level of arousal.
Based on these considerations, BoNTA is a ﬁrst-line
treatment choice if the upper and lower limb spasticity is
focal and reversible without contracture [2].
The efﬁcacy and safety of BoNTA in patients with post-
stroke lower limb spasticity have been suggested by
randomized-controlled trials of limited scale [3–8] and
meta-analysis [9]. The efﬁcacy of BoNTA in patients with
severe brain injury has also been demonstrated in a
randomized-control trial [10]. Approved treatments of
spasticity in Japan include peripheral and central muscle
relaxants, alcohol, phenol block, and intrathecal baclofen
(only in cases of severe spastic paralysis). We conducted a
clinical study to evaluate the efﬁcacy and safety of BoNTA
in Japanese patients with post-stroke lower limb spasticity
who received a single placebo-controlled injection of
BoNTA followed by open-label repeated treatment of up to
three sessions. This article reports the efﬁcacy and safety
results of the double-blind phase.
Methods
A multicenter, randomized, double-blind, parallel-group,
placebo-controlled study in Japanese patients with post-
stroke lower limb spasticity was conducted in 19 Japanese
medical institutions in Japan between May 2007 and April
2008. The study was approved by the Institutional Review
Board and was conducted according to the Declaration of
Helsinki and the GCP; all patients signed informed consent.
Patients
Male or female patients aged 20–80 years and weighing at
least 50 kg were eligible if they had had a stroke at least
6 months prior to treatment and had equinus deformity
(plantar ﬂexion of the ankle) as demonstrated by a score of
[3 for ankle ﬂexors on the Modiﬁed Ashworth Scale
(MAS) [11].
Exclusion criteria were bilateral hemiplegia or quadri-
plegia; ﬁxed contractures in the ankle; profound atrophy of
the muscles to be injected; prior treatment with surgery,
phenol/ethanol block, muscle afferent block (MAB),
intrathecal baclofen, or any botulinum toxin serotype; and
current use of peripheral muscle relaxants. Women were
excluded if they were pregnant, lactating, potentially
pregnant, or planning to become pregnant during the course
of the study.
Procedures
The primary study objective was to conﬁrm the superior
efﬁcacy of a single treatment of BoNTA 300 U over pla-
cebo in patients with post-stroke lower limb spasticity using
the MAS ankle score. MAS is widely used for the assess-
ment of muscle tone and spasticity in lower limbs [5, 7–10].
Investigators were trained in the procedures to assess the
MAS ankle score at the studystart. Patients were assessed in
the prone position, and the ankle was examined from the
edge of the examination table for the MAS ankle score. The
study included a screening examination (2–4 weeks before
the treatment), a single treatment, and a 12-week follow-up
period. Patients visited the center at screening, on the
treatment day, and at weeks 1, 4, 6, 8, and 12 for speciﬁed
examinations, observations, and assessments.
Treatments
Investigational drug
One vial of BoNTA (GSK1358820, BOTOX
, Allergan,
Inc., Irvine, CA) contains 100 U of a speciﬁc formulation
(Formulation 9060X) of botulinum toxin type A, 0.5 mg
human serum albumin, and 0.9 mg sodium chloride per
vial, which requires reconstitution prior to injection. The
indistinguishable placebo contained 0.9 mg sodium
chloride per vial. Each vial was reconstituted with 8 ml of
non-preserved physiological saline resulting in a ﬁnal
concentration of 1.25 U BoNTA per 0.1 ml or placebo.
Drug dose and muscle selection
Drug dose and muscle selection was based on the Austra-
lian package insert [12]. Patients were randomly assigned
to receive a single injection of 300 U of BoNTA or placebo
and were injected with 75 U of BoNTA or placebo per
muscle into each of the following: medial head of the
gastrocnemius, lateral head of the gastrocnemius, and
soleus muscle and tibialis posterior muscle (divided into
three sites per muscle). Patients in the placebo group
received the same volume of placebo solution into the same
number of injections/muscles.
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needle were used to identify the proper muscles and
facilitate injection in all patients.
Randomization
After screening, each eligible patient was randomized 1:1
to receive either BoNTA or placebo injection on the
treatment day. The person responsible for randomization
prepared a randomization code table, and it was concealed
from all investigators and all study personnel until data
collection and analysis were completed.
Assessments
Efﬁcacy
MAS The muscle tone of the ankle was assessed by the
investigator using the MAS [11] at screening, pre-injection
on the treatment day (baseline), and at weeks 1, 4, 6, 8, and
12 or at study withdrawal.
Gait pattern scale (physician’s rating scale) The inves-
tigator assessed the gait pattern while the patient walked
10 m using the Physician’s Rating Scale [13] (Table 1)
pre-injection on the treatment day and at weeks 1, 4, 6, 8,
and 12 or at study withdrawal. This scale of -1 (worst) to 9
(best) based on three parameters (initial foot contact, foot
contact at midstance, and gait-assisting devices) is an
observational gait scale originally developed by Koman
et al. [14]., modiﬁed by Corry [15], and subsequently
modiﬁed by Boyd et al. [13]. In this study, gait parameters
that were suitable for the intended purpose were selected
from the original parameters.
Speed of gait The investigator or clinical research coor-
dinator measured the time (seconds) the patient took to
walk 10 m straight ahead pre-injection on the treatment
day and at weeks 1, 4, 6, 8, and 12 or at study withdrawal.
Clinical global impression (CGI) At screening, pre-
injection on the treatment day, and at weeks 1, 4, 6, 8, and
12 or at study withdrawal, the global impression of func-
tional disability on the visit day was assessed using the
Numeric Rating Scale, with -5 indicating worst possible
and 5 best possible rating, by the investigator, the patient,
and the physical or occupational therapist.
Safety Adverse events were recorded throughout the
study. Laboratory tests were performed at screening and at
week 12 or at study withdrawal. Vital sign assessments
(pulse rate and blood pressure) and 12-lead electrocardi-
ography were performed on the treatment day and week 12
or at study withdrawal.
Data analysis
The sample size was chosen based on the previous study
[6]. Assuming a mean difference of 5 points in the AUC for
the MAS ankle score change between BoNTA and placebo
based on the results and a SD value of 7.5 for both treat-
ments, 49 subjects per group were be required to provide
90% power at the 5% level of signiﬁcance (two-sided)
using t-test to achieve superiority over placebo. Assuming
approximately 20% of dropouts, the sample size of 60
subjects per group (120 subjects in total) was chosen.
Efﬁcacy data were analyzed using the full analysis set
(FAS), deﬁned as all randomized patients that received
study treatment and had at least one MAS ankle assessment
after treatment.
The AUC of the change from baseline in the MAS ankle
score was the primary endpoint. Considering the differ-
ences of individual peak efﬁcacy, the assessment over the
treatment period by AUC as summary index was consid-
ered to provide more accurate evaluation than assessment
at a speciﬁc time point [16–18], resulting in more accurate
evaluation of efﬁcacy of BoNTA compared to placebo.
MAS ankle scores at individual time points were also
evaluated. For each patient, the change from baseline (the
day of the treatment) in the MAS ankle score at each time
point was calculated; ‘‘1?’’ was analyzed as score 1.5.
Table 1 Gait pattern scale (Physician’s Rating Scale)
Gait parameter Deﬁnition Limb
score
Initial foot contact Toe 0
Forefoot 1
Foot-ﬂat 2
Heel 3
Foot contact at
midstance
Toe/toe (equinus) -1
Foot-ﬂat/early heel rise 0
Foot-ﬂat/no early heel rise 1
Occasional heel/foot-ﬂat 2
Heel/toe (normal roll-over) 3
Gait assistive
devices
Walker (forward/posterior) with
assistance
0
Walker (independent) 1
Crutches, sticks 2
None, independent for 10 m 3
Total score (score =- 1–9 per limb)
Adapted from: Boyd RN, Graham HK. Objective measurement of
clinical ﬁndings in the use of botulinum toxin type A for the
management of children with cerebral palsy. European Journal of
Neurology. 1999;(4):S23–S35 (Partial quoted)
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time (horizontal axis), and the area under the resultant
curve was obtained. A decrease from baseline resulted in a
negative (-) AUC value, while an increase from baseline
resulted in a positive (?) AUC value. The difference in the
mean AUC between the BoNTA group and the placebo
group was tested using a t-test. The point estimate and the
95% CI of the mean group difference were also calculated.
Changes from baseline in the MAS ankle score, the
Physician’s Rating Scale, the speed of gait, and the CGI at
each time point were summarized by group; the Wilcoxon
test was used to determine statistical differences between
the BoNTA group and the placebo group.
Safety data were analyzed for the safety population
(SP), deﬁned as all patients that received study treatment.
Results
Demographics
Of the 131 patients who provided informed consent, 120
were randomized and received study treatment (58 BoNTA,
62 placebo). One hundred thirteen patients completed the
study (Fig. 1). Seven patients prematurely withdrew after
randomization: three (BoNTA group) due to adverse
events, three (BoNTA group) consent withdrawal, and one
(placebo group) deviation from the protocol (met exclusion
criteria). Demographic and baseline characteristics except
gender were comparable between the groups. More men
than women were included in both groups (Table 2).
Primary endpoint
AUC of the change from baseline in MAS ankle scores
After treatment the ankle MAS AUC was signiﬁcantly
lower in the BoNTA group than in the placebo groups,
demonstrating the superiority of BoNTA to placebo (mean
difference, -3.428; 95% CI, -5.841 to -1.016;
p = 0.006; t test) (Fig. 2).
Secondary endpoints
MAS
After treatment, in the ankle MAS at individual time points
a signiﬁcantly greater decrease from baseline was noted at
weeks 4, 6, and 8 in the BoNTA group compared to the
placebo group (p\0.001) (Fig. 3; Table 3).
BoNTA=Botulinum toxin type A 
Withdrawn before randomization 
11 
Analysed 
58 
(Full Analysis Set) 
Analysed 
62 
(Full Analysis Set) 
BoNTA 
58 
Placebo 
62 
Completed  
52 
Completed  
61 
Withdrawn: 1 
Protocol Violation: 1 
Withdrawn: 6 
Adverse Event: 3 
Subject’ request: 3 
Informed consent obtained 
131 
Randomized 
120 
Fig. 1 Study patient ﬂow chart.
BoNTA Botulinum toxin type A
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After treatment a slight increase from baseline in the
Physician’s Rating Scale score was noted for both groups,
and no signiﬁcant group difference was observed at any
time point (Table 3).
Gait speed
Gait speed measured as the time required for a 10-m walk
started to decrease at week 4 in the BoNTA group; how-
ever, the same trend was noted in the placebo group, and no
signiﬁcant group difference was observed at any time point
(Table 3).
CGI
There was a signiﬁcantly greater increase in the CGI score
by the investigator noted in the BoNTA group compared to
the increase in the CGI in the placebo group at weeks 4, 6,
and 8 (p = 0.016 to 0.048, Wilcoxon test).
No signiﬁcant group difference was noted in the CGI
scores by the patient and by the physical or occupational
therapist at any time point (Table 3).
Safety
Adverse events
Adverse events were reported in 45% (26/58) in the
BoNTA group and 44% (27/62) in the placebo group
during the 12-week follow-up period.
Serious adverse events were reported in 9% (5/58) in the
BoNTA group and 2% (1/62) in the placebo group during
the 12-week follow-up period. All of the serious adverse
events except for myalgia were considered to be unrelated
to BoNTA. All of these events were resolved.
Investigator-determined treatment-related adverse
events were reported during the 12-week follow-up period
in 12% (7/58) in the BoNTA group and 11% (7/62) in the
placebo group (Table 4). All of the treatment-related
adverse events reported in the BoNTA group were mild or
moderate in intensity.
Other safety endpoints
There were no marked changes in any laboratory data,
blood pressures, pulse rates, or EKGs in any group after the
treatment.
Discussion
This study demonstrated the superiority of 300 U BoNTA
to placebo to reduce muscle tone based on the AUC of the
change from baseline in the MAS ankle score as the pri-
mary efﬁcacy endpoint. At individual time points the MAS
Table 2 Demographics and patient characteristics (FAS population)
BoNTA Placebo
N = 58 N = 62
Age (years) 62.4 ± 8.7 62.5 ± 9.3
Race (Japanese) 58 62
Gender (female/male) 8/50 16/46
Weight (kg) 67.6 ± 10.0 65.0 ± 9.5
Mean duration of stroke (month) 80.8 ± 72.8 72.0 ± 60.3
MAS 3.28 ± 0.45 3.24 ± 0.43
Gait pattern scale (Physician’s
Rating Scale)
3.10 ± 2.35 3.23 ± 2.02
Speed of gait (s)
a 60.96 ± 49.69 52.83 ± 51.57
CGI
Investigator -1.33 ± 1.69 -1.26 ± 1.78
Patient -1.28 ± 1.89 -0.92 ± 2.05
Physical/occupational therapist -1.26 ± 2.00 -1.23 ± 2.04
Values are mean ± SD, except where stated otherwise
a Time (s) that the patients took to walk 10 m straight ahead
BoNTA Botulinum toxin type A, CGI clinical global impression, FAS
full analysis set, MAS Modiﬁed Ashworth Scale
-20
-18
-16
-14
-12
-10
-8
-6
-4
-2
0
A
U
C
BoNTA
N=58
Placebo
N=62
-8.513
-5.058
*
Treatment
group
BoNTA
(N=58)
Placebo
(N=62)
Mean -8.513 -5.085
SD 6.6904 6.6496
Median -9.5 -2
Min. -22 -25.5
Max. 0 0
Mean
difference
95%CI
p value
-3.428
-5.841,-1.016
0.006
Fig. 2 Mean AUC for MAS of ankle. AUC area under the curve,
BoNTA Botulinum toxin type A, MAS Modiﬁed Ashworth Scale.
*p\0.05 (t test). AUC was obtained by plotting changes from
baseline (vertical axis) of MAS against time point (horizontal axis).
The ‘‘1?’’ was analyzed as score 1.5. A decrease from baseline
resulted in a negative (-) AUC value
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123ankle score showed a signiﬁcantly greater decrease from
baseline for the BoNTA group compared to placebo at 4, 6,
and 8 weeks after treatment. These results demonstrated
the efﬁcacy of BoNTA injections for improvement of
spasticity in the ankle in Japanese patients by the same
action mechanism of BoNTA as in Caucasian patients
demonstrated in previous studies [3–10].
Patients with spasticity can suffer from impaired walk-
ing ability that includes equinus foot; consequently this
disability negatively affects performance of the patient’s
activities of daily living (ADL). As secondary endpoints
the patient’s gait pattern and gait speed were assessed to
determine the efﬁcacy of BoNTA for improving these
measures of ambulation. Both BoNTA and placebo treat-
ments were associated with slight increases in the Physi-
cian’s Rating Scale score (i.e., gait pattern scale), and no
signiﬁcant difference was noted between BoNTA and
placebo. In addition, the time required for 10-m walking
decreased after treatment with either BoNTA or placebo,
and no signiﬁcant difference was noted between the two
treatments.
The lack of effect on ambulation for subjects treated
with BoNTA may be due to their need to change from
spastic gait attributable to talipes equinovarus to the gait
with normal grounding of the foot through alleviation of
the spasticity of the ankle. Furthermore, the mean duration
of stroke in this study was 76.3 months (approximately
6 years). This extended duration of spasticity would allow
for accommodation of physical changes as patients become
accustomed to walk making use of their spasticity, as set
motor patterns are changed with rearrangement of under-
lying neural circuits. This short-duration study (3 months)
may be insufﬁcient to learn the gait with normal grounding
of the foot and adequately modify the neural circuit.
Therefore, the patients’ gait scale was not improved much.
It may be possible that rehabilitation could be facilitated
after treatment with BoNTA, but that assessment is beyond
the scope of this study. In this study patients were allowed
concomitant use of rehabilitation, ‘‘but the frequency and
content of rehabilitation should not be changed’’ during
this study. Since the rehabilitation training was not
designed or modiﬁed to accommodate for the change in
muscle tone associated the synergic effect of rehabilitation
including the walk training and BoNTA administration did
not meet expectations. The effects of BoNTA on gait
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Fig. 3 Mean of change from baseline in MAS of ankle. BoNTA
Botulinum toxin type A, MAS Modiﬁed Ashworth Scale. *p\0.05
(Wilcoxon test)
Table 3 Mean and SD of change from baseline in MAS, PRS, speed
of gait, and CGI
BoNTA (N = 58) Placebo (N = 62) p value
a
n Mean ± SD n Mean ± SD
MAS
Week 4 56 -0.88 ± 0.69 62 -0.43 ± 0.72 \0.001
Week 8 54 -0.82 ± 0.66 61 -0.43 ± 0.68 \0.001
Week 12 54 -0.56 ± 0.69 61 -0.40 ± 0.58 0.240
Gait pattern scale (Physician’s Rating Scale)
Week 4 54 0.54 ± 1.22 60 0.63 ± 1.45 0.688
Week 8 54 0.61 ± 1.19 59 0.78 ± 1.81 0.825
Week 12 53 0.55 ± 1.26 60 0.58 ± 1.57 0.775
Speed of gait
Week 4 54 -6.10 ± 22.86 61 -7.37 ± 20.78 0.209
Week 8 54 -3.14 ± 35.78 60 -8.19 ± 18.63 0.367
Week 12 53 -10.14 ± 26.93 61 -8.53 ± 24.71 0.585
CGI
Investigator
Week 4 56 1.09 ± 1.25 61 0.64 ± 1.07 0.048
Week 8 54 1.13 ± 1.32 61 0.59 ± 1.23 0.016
Week 12 53 0.81 ± 1.30 61 0.52 ± 1.27 0.166
Patient
Week 4 56 0.75 ± 1.58 61 0.44 ± 1.76 0.120
Week 8 54 1.00 ± 2.03 61 0.70 ± 1.98 0.281
Week 12 53 0.49 ± 1.53 61 0.49 ± 2.18 0.409
Physical/occupational therapist
Week 4 54 0.64 ± 1.27 61 1.07 ± 1.38 0.119
Week 8 53 1.04 ± 1.78 61 1.00 ± 1.64 0.589
Week 12 53 1.02 ± 1.34 61 0.97 ± 1.51 0.600
a Wilcoxon test
BoNTA Botulinum toxin type A, CGI clinical global impression,
MAS Modiﬁed Ashworth Scale, PRS Physician’s Rating Scale
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speed should be further assessed in a long-term treatment
setting where learning a modiﬁed motor pattern and the
underlying neural modiﬁcations may be established. Pos-
sible improvement in equinus foot after long-term BoNTA
treatment with combined use of rehabilitation is expected
to allow correction of walking patterns and thereby reduce
the systemic burden of walking. Increasing walking dis-
tance (or decreased time required for a given walk) may
expand the range of patient activities and lead to improved
ADL. Further long-term study in the open label extension
is important to clarify the perceived beneﬁts and changes in
the ADL and quality of life.
A signiﬁcantly greater increase in the CGI score by the
investigator was noted in the BoNTA group compared to
the placebo group at weeks 4, 6, and 8, but no signiﬁcant
difference was noted by the patient or physical/occupa-
tional therapist. Since the result of the Physician’s Rating
Scale score and speed of gait was not signiﬁcant in this
study, the treatment outcome seems to have fallen short of
the expectation of patients and the physical/occupational
therapist. These results differ from previous reports [9, 19]
that BoNTA improves the impression of functional dis-
ability assessed by the Global Assessment Scale. Beneﬁcial
effects of BoNTA on gait pattern and speed of gait may be
more apparent after a longer treatment period.
No marked difference was noted in the frequency of
treatment-related adverse events between groups [7 (12%)
with BoNTA vs. 7 (11%) with placebo]. Injection or
administration site pain was reported in four patients (7%)
in the BoNTA group and one patient (2%) in the placebo
group. This is an event associated with intramuscular
injection, and caution should be exercised in injecting
BoNTA. There were no reports of treatment-related
adverse events characteristic of oral muscle relaxants
(sleepiness, feelings of weakness, and a light-headed feel-
ing). In this study, the safety of BoNTA was similar to
observations from a pooled analysis of the safety of the
same formulation of BoNTA that included nine double-
blind, placebo-controlled studies of spasticity patients after
stroke [20].
An important consideration for the use of BoNTA is the
serotype and formulation. As BoNTA is a biological
product, it is not interchangeable with other products
because of the complexity, between-product variability,
and speciﬁcity of the manufacturing processes. Conse-
quently, botulinum toxin products are non-interchangeable
with any other botulinum toxins [21–27].
The results of this study indicate the efﬁcacy of BoNTA
300 U without any dose-limiting adverse events. This
study demonstrated the safety and efﬁcacy of BoNTA
300 U into the muscles of lower limbs of patients with
post-stroke ankle spasticity.
As a drug product for local administration, BoNTA can
be directly injected into a target muscle with localized
hypertonia to relax the muscle. Its direct relaxant effect on
the muscle causing spasticity may reduce equinus foot and
improve walking ability, leading to the improved ADL
performance of patients. This effect is expected to reduce
the dependence on care when walking inside or outside as
well as to reduce the burden for patients, family, and
caregivers. The observed persistence of the efﬁcacy of a
single BoNTA treatment for 12 weeks suggests possible
better treatment compliance compared to the use of oral
muscle relaxants that require daily medication [28].
Moreover, BoNTA may be an effective treatment choice
for patients who have difﬁculty treating spasticity with oral
muscle relaxants because of adverse drug reactions.
The long-term efﬁcacy and safety, and the effects on
rehabilitation of BoNTA will be evaluated using the data
obtained in the open-label phase.
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